IMVT — Immunovant Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapMomentum Trap

Annual balance sheet for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	494	377	635	714	902
Net Total Accounts Receivable
Net Total Receivables	12.9	0.885	5.5	2.51	3.95
Prepaid Expenses
Total Current Assets	513	404	666	768	949
Net Property, Plant And Equipment	2.63	1.5	0.595	0.942	0.515
Other Long Term Assets
Total Assets	516	406	666	776	957
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	44.5	43.3	48.6	68.8	104
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	45.7	43.3	48.6	68.8	104
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	470	362	618	707	853
Total Liabilities & Shareholders' Equity	516	406	666	776	957
Total Common Shares Outstanding